EU Approvals: Rinvoq Cleared For RA
AbbVie's Selective JAK Inhibitor A Driver Of Future Growth
Executive Summary
AbbVie’s upadacitinib has become the latest JAK inhibitor to be approved in the EU for active rheumatoid arthritis, and its selectivity could allow it to compete effectively with established therapies including other JAK inhibitors, TNF-inhibiting biologics and biosimilars.